CBU
ALLO icon

CIBC Bancorp USA’s Allogene Therapeutics ALLO Stock Holding History

CIBC Bancorp USA’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$20K Buy
+16,163
New +$19.3K ﹤0.01% 1454

Other funds holding ALLO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

CIBC Bancorp USA's ALLO Position: Q3 2025 in Review

CIBC Bancorp USA opened a new position in Allogene Therapeutics (ALLO) in Q3 2025: 16,163 shares worth $20K. The stake represents ﹤0.01% of the portfolio and ranks #1454 among its holdings.

170 funds tracked by Wall St. Rank hold ALLO as of Q3 2025.

  • CIBC Bancorp USA held 16,163 shares of Allogene Therapeutics worth $20K as of Q3 2025.
  • Allogene Therapeutics was a new CIBC Bancorp USA position in Q3 2025.
  • Allogene Therapeutics made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q3 2025, its #1454 holding.
  • 170 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q3 2025.

Based on CIBC Bancorp USA's 13F filing for Q3 2025, filed 12 Nov 2025.